CIRB #H-42687/ CTSU #A011801 (CompassHER2-RD): CompassHER2 Residual Disease РA Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib 

CIRB #H-43958/ ETCTN 10525: A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer (pending CIRB approval)

CIRB #H-44585/ SWOG #S2212 (SCARLET): Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
(pending CIRB approval)

CIRB #H-44586/ CTSU #A012103 (OptimICE-pCR): De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy (pending CIRB approval)

WCG IRB #H-44464/ DFCI #23-355 (TRADE):: The TRADE Study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients With Early-Stage HR-positive and HER2-negative Breast Cancer (pending CIRB approval)

CIRB #H-42956/ ETCTN #10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (temporary closure)

IRB #H-33188/ BMC #DOSI: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI) (temp closure)

IRB #H-37386/ CTSU #EA1151 (TMIST): Tomosynthesis Mammographic Imaging Screening Trial